The company currently is conducting a special protocol assessment with the U.S. Food and Drug Administration (FDA) for a phase III study of its Imagify ultrasound contrast agent.

The study will compare stress ultrasound with Imagify to unenhanced stress ultrasound for detecting coronary artery disease.